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Abstract 
Background: To investigate the effects of vitamin D3 on the surgical outcome 
of pediatric patients undergoing cardiac surgery for congenital heart 
conditions.  
Materials and Methods: Ninety pediatric cardiac surgery patients referred 
for preoperative evaluation were enrolled. Patients with insufficient vitamin 
D3 levels received intramuscular vitamin D3 (300,000 IU) three days before 
the surgery and those with final vitamin D3 level of ≥30 ng/dl were included 
and divided into 3 groups (Group A: abnormal Vit D levels, no Vit D 
treatment; Group B: abnormal Vit D levels, Vit D treatment up to normal 
serum Vit D levels before surgery; Group C: normal baseline Vit D levels, no 
supplemental Vit D treatment). Interleukin 1, 6, 10, tumor necrosis factor-
alpha, vital signs, and arterial blood gas parameters were measured before the 
surgery and at 6 and 24 hours after cardiopulmonary bypass. Data on total 
hospital stay, reoperation rates, and inotropes scores were retrieved. 
Additionally, postoperative measures including hemodynamic factors, blood 
pressure, heart rate, cardiac output, electrocardiography changes, chest-tube 
drainage, and ventilation-related factors (i.e. respiratory rate, arterial blood 
gas, respiratory resistance, intubation time, …) were recorded.  
Results: We observed a significant increase in post cardiopulmonary bypass 
levels of IL-10 and IL-6 in all groups (p<0.002) regardless of vitamin D 
treatment status; however, no significant difference was seen in levels of IL-
1 and TNF-alpha. Groups B had more patients with critical levels of VIS 
scores compared to groups A and C (p<0.002). Furthermore, no differences 
in hemodynamic and metabolic parameters were observed.  
Conclusion: No significant difference in the rates of postoperative 
parameters in patients with normal and those with deficient levels of vitamin 
D3 was observed.  
Keywords: Vitamin D, Congenital heart disease (CHD), Cardiac surgery, 
Cardiopulmonary bypass, Vitamin D3 supplementation 
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Introduction 
Twenty-eight percent of all major congenital 
anomalies consist of heart defects (1). The incidence of 
congenital heart disease (CHD) has been reported to be 
approximately 8 in 1000 live births, and 40,000 
surgeries are performed in the United States annually 
to treat this condition (2, 3). The effects of Vitamin D3 
deficiency and its contribution to congenital heart 
disease has long been known and proven (4). 
Newborns with vitamin D3 deficiency are found to 
have a greater prevalence of patent foramen ovale 
(PFO), atrial septal defect (ASD), ventricular septal 
defect (VSD), and overriding of the great vessels (5, 
6). The mechanism of vitamin D3 deficiency leading 
to these congenital malformations is not well 
understood to this date. Pediatric patients with vitamin 
D3 deficiency also experience a more eventful 
postoperative course, greater mortality, greater 
postoperative complications, and longer stay in the 
ICU (2). The literature shows that in children with 
CHD, preoperative optimization of vitamin D levels 
improves the postoperative outcomes (7). 
Vitamin D3 (1, 25 dihydroxy vitamin D) is a 
pleiotropic hormone, important for the function of 
multiple organs. Sufficiency for vitamin D3 is defined 
as levels above 75-80 ng/dl, a deficiency is defined as 
levels below 50 ng/dl, and severe deficiency is defined 
as levels below 30 ng/dl (8). 
The best study to date comes from a large 
prospective observational study published by 
Zitterman and colleagues, wherein, they demonstrated 
that compared to normal vitamin D3 levels (75-100 
ng/dl) having a value below 50 ng/dl was significantly 
associated with MACCE risk (i.e., in-hospital death, 
myocardial infarction, duration of hospitalization, or 
stroke) (9). The traditional approach to correct vitamin 
D levels involves oral supplementation over a period 
of 2 to 3 months (10, 11). Another regimen commonly 
referred to as Stoss therapy (or mega dose therapy) 
involves a single oral or intramuscular administration 
of 50,000 to 600,000 IU (Bordelon, P. Recognition and 
management of vitamin D deficiency). The efficacy of 
different vitamin D replenishment regimens to achieve 
the desired preoperative serum levels can be inferred 
from several recently completed studies performed on 
healthy children (12, 13). Early studies of vitamin D 
and its effects on the immune system demonstrated 
vitamin D receptor expression in both T and B cells 
(14). Notably, VDR expression by these cells was only 
immunologically functional inactive, proliferating 
cells, suggesting an anti-proliferative role for vitamin 
D3 in these cells (15). Vitamin D3 targets T helper (Th) 
cells, and it enforces its effects by suppressing their 
proliferation and reducing their production of 
cytokines (16). Activation of naive Th cells by 
antigens, in turn, leads to the generation of Th cell 
subgroups with distinct cytokine profiles: Th1 (IL-2, 
IFN γ, tumor necrosis factor-alpha) and Th2 (IL-3, IL-
4, IL-5, IL-10) that respectively support cell-mediated 
and humoral immunity (17, 18). 
Methods 
The study was performed after ethical approval from 
the University Ethics Committee (ethics code: 
IR.SBMU.RAM.REC.1394.624) and taking informed 
written consent. A total of 318 consecutive patients 
were evaluated by the anesthesiology team between 
April 2016 and April 2018 and assessed for being 
included in this study. Our inclusion criteria consisted 
of enrolling patients under the age of 16 with a 
confirmed diagnosis of congenital heart disease. We 
excluded patients with insufficient levels of vitamin D 
who failed to demonstrate a proper level of vitamin D 
level after intramuscular injection. A total of 179 
patients consented to take part in this study. Of the 
consented patients, 30 were found to have normal 
serum levels of vitamin D while the remaining 149 
were vitamin D deficient. Patients with deficient levels 
of vitamin D were randomized to either treatment 
(received intramuscular vitamin D injection) or 
placebo (did not receive vitamin D). The reception 
desk at the surgical ward handing the admitting nurse 
a sealed envelope containing a code representing the 
group that patients would enter did the randomization. 
In the vitamin D deficient population, no intervention 
was undertaken in 30 patients, while another 30 
received vitamin D treatment and had adequate levels 
preoperatively. The remaining 89 patients were 
excluded from the study because their serum vitamin 
D levels failed to reach the threshold level set by our 
study (i.e., 30 ng/dl). 
A total of 90 patients were included in our final 
analysis of data. We divided our patients into three 
groups as follows. Group A were patients with 
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abnormal levels of vitamin D who did not receive any 
treatment. Group B consisted of patients who had 
abnormal levels of vitamin D and received treatment 
and achieved normal levels before surgery. Group C 
patients were those with normal baseline levels of 
vitamin D who did not require treatment with vitamin 
D. 
Our intervention consisted of a single 
intramuscular injection of 300,000 IU of vitamin D3 
three days before the operation in the A group. We also 
sent blood samples to the lab for evaluating major 
inflammatory mediators such as interleukins 1, 6, 10 
and tissue necrotizing factor-alpha (TNF alpha) before 
starting the CPB as well six and twenty-four hours after 
removing patients from CPB. Other items that we 
measured intraoperatively and postoperatively in the 
ICU were data on hemodynamic parameters such as 
blood pressure, Spo2, heart rate, EKG patterns, body 
temperature, serum electrolytes, arterial blood gas, 
time spent on the pump, inotropes, amount of blood, 
and blood products, extubation times, ICU stay, 
hospital stay, morbidity, and mortality. 
 
Results 
Demographics: Ninety consecutive pediatric patients 
undergoing cardiac surgery were enrolled in this study. 
The average age was 3.69±1.97 years, while there were 
45 males and 45 females who were enrolled in the 
study. The underlying disease of the patients and their 
frequencies are demonstrated in Table 1.  
In the next step, the patients who were enrolled 
in the study were then divided into three different 
groups (A, B & C) each including 30. Patients in 
Group A (n=30) had subnormal levels of vitamin D 
ranging 5-23 nm/ml (mean 12.8 nm/ml, SD ±5.15), this 
group did not receive any vitamin treatment. Group B 
consisted of children with subnormal vitamin D levels 
ranging 5-29 nm/ml (mean 17.83 nm/ml, SD±6.85) 
who received a one-time treatment of 300,000 IU 
intramuscular of vitamin D three day before surgery, in 
this group the vitamin D levels were checked and those 
that were above 30 ml were enrolled in the study. 
Group C included children with normal vitamin D 
levels ranging from 30-112 nm/ml (mean 50.71 nm/ml, 
SD ±20.49) and did not receive any vitamin D 
treatment before their surgery. 
 
Cytokine levels: Levels of four different cytokines 
including IL-1, IL-6, IL-10, and TNF-alpha were 
checked just before surgery, 6 and 12 hours after 
surgery in all patients, and the change in their levels 
were documented (Table 2). The levels of IL-1 and 
TNF-alpha were not significantly different in any of 
the three different groups preoperatively and after 
initiating the CPB. On the other hand, levels of IL-10 
 
 
Table 1- Indicator for patient’s level of critical status postoperatively * 
 TF PS AVC AS PVR VSD ASD TGA Female/Male 
ratio 
Age 
Group A 17 1 2 1 0 4 5 0 15/15 3.97±2.2 years 
(range 4 days-11 
years) 
Group B 19 0 0 1 1 5 3 1 15/15 2.79±1.9 years 
(range 5 months-
14.0 years) 
Group C 12 5 1 0 2 7 2 1 15/15 4.30±1.8 years 
(range 1.00-11.00 
years) 
Total 48 6 3 2 3 16 10 2 45/45 3.69±1.97 (4 days-
14 years) 
* TF: Tetralogy of Fallot; PS: Pulmonary Stenosis; AVC: Atrioventricular Canal; AS: Congenital Aortic Stenosis; PVR: Pulmonary 
Valve Replacement; VSD: Ventricular Septal Defect; ASD: Atrial Septal Defect; TGA: Transposition of Great Arteries 
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and IL-6 increased significantly in all groups after the 
initiation of the CPB. Preoperative IL-1 levels were 
comparable in all three groups but IL-6 levels were 
significantly higher in group B (3.59±10) and group C 
(4.86±9). IL-10 had the highest concentration in group 
B (20.95± 48). The levels of IL-1 were lower than 
normal in all three groups six hours after initiating CPB 
(1.78), but levels of IL-6 were significantly higher in 
group B compared with other groups six hours after the 
surgery (54.00±51). Levels of IL-10 were higher in 
both group B (95.42±79) and group C (86.88±83) 
when compared with group A (55.13±44.98). 
However, 24 hours after the surgery, levels of IL-1, IL-
6, and IL-10 were significantly reduced (Table 2) 
 
Hemodynamic and metabolic measurements: 
Metabolic measurements including hematocrit level, 
lactate level, PaCO2, minute ventilation time, and 
intravenous fluid therapy were measured for all groups 
and reported (Table 3). Levels of various 
hemodynamic entities including systolic and diastolic 
Blood Pressure, heart rate, SpO2, as well as ECG were 
documented just preoperatively, at the time of the 
surgery, and postoperatively for all patients, and the 
Table 2- Cytokine levels in the study groups. 
 Group A (n=30) Group B (n=30) Group C (n=30) P value 
IL-1     
Before surgery 1.14±0.64 1.00 1.45±2.37 0.638 
6 hrs after CPB 1.28±0.80 1.30±1.42 1.59±2.93 0.261 
24 hrs after CPB 1.12±0.34 1.00 1.40±2.19 0.185 
p-value1 0.422 -- 0.203  
IL-6     
Before 1.60±2.92 3.59±5.10 4.86±9.21 0.025 
6 hrs 31.58±21.68 54.03±51.95 35.75±35.02 0.454 
24 hrs 14.22±22.38 19.61±27.10 18.73±25.82 0.104 
p-value <0.001 <0.001 <0.001  
IL-10     
Before 7.00±14.78 20.95±48.68 14.80±26.24 0.414 
6 hrs 55.13±44.98 95.42±79.20 86.88±83.85 0.180 
24 hrs 25.16±56.33 25.35±48.53 31.14±56.28 0.493 
p-value <0.001 <0.001 <0.001  
TNF-α     
Before 1.05±0.03 1.00 1.02±0.13 0.212 
6 hrs 1.05±0.09 1.00 1.32±1.21 0.169 
24 hrs 1.10±0.28 1.00 1.40±2.19 0.222 
p-value 0.122 -- 0.446  
1. Results of Repeated Measures ANOVA 
For IL-6 differences between groups A and B (p=0.025) and groups A and C (p=0.007) are significant.  
 
 
Table 3- Metabolic and fluidic variables in the study groups 
 Group A (n=30) Group B (n=30) Group C (n=30) P value 
Hematocrit 36.50±6.97 34.87±6.06 34.87±6.06 0.616 
Lactate 4.04±2.46 4.31±2.73 4.22±3.20 0.958 
Mechanical Ventilation Time 10.74±4.64 17.49±11.56 9.47±5.80 <0.001 
Arterial Pressure of CO2 
(PaCO2) 
37.57±14.12 39.20±12.19 40.93±11.26 0.211 
Intravenous fluids 46.17±19.90 43.83±18.23 40.34±21.29 0.325 
Hemodynamic changes including Hematocrit, lactate, and CO2 levels were not significantly changed in all groups. Group B patients 
had a longer ICU stay. The range of hemodynamic changes and secretion in all groups were comparable. 
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representative values were selected to obtain an 
average value for each group (Table 4). No differences 
in hemodynamic and metabolic parameters were 
observed amongst the three groups.  
 
Patient morbidity and mortality: Total number of 
days patients stayed in ICU and hospital were 
measured for all patients as well as each group 
separately. Besides, ionotropic score and vasoactive 
ionotropic score were measured for all patients 
postoperatively the results of which are summarized in 
Tables 4 and 5. There were a greater number of patients 
in the B group (n=23) with critical levels of the 
vasoactive inotropic score, (defined as a VIS score of 
2 or greater) compared to groups A and C (Figure-1).  
 
Statistical Analysis: All continuous variables were 
presented as mean and standard deviation. The 
normality of the variables was tested by Kolmogorov 
Smirnov test and proper graphs. One-way analysis of 
variance (ANOVA) was employed for comparison of 
continuous variables among three groups (A, B and C) 
followed by Tukey post hoc test. For variables that 
were not normally distributed, nonparametric Kruskal-
Wallis test was applied. To evaluate time effects, i.e. 
before treatment, 6 and 24 hours after treatment, 
ANOVA method was employed. P-values less than 
0.05 were considered as a significant difference. 
 
Discussion 
Several interconnected factors may play an important 
role in outcome of surgery as well as the duration of 
hospital stay in patients with congenital heart disease; 
these include elevated levels of pro-inflammatory 
factors, vitamin D deficiency, and the duration of CPB 
use during the operation. Ample evidence in the 
literature points to the fact that elevated levels of 
interleukins lead to vascular damage resulting in 
hemodynamic instability and coagulopathy. The main 
stay of treatment to reduce these factors is the use of 
high dose systemic corticosteroids as well as 
Table 4- Summary of hemodynamic measures. 
 Group A (n=30) Group B (n=30) Group C (n=30) P value 
Systolic BP 91.27±15.34 99.93±24.41 97.07±19.81 0.437 
Diastolic BP 53.00±12.46 58.82±12.47 53.61±12.84 0.166 
Heart Rate 128.33±21.01 124.03±17.92 129.87±20.96 0.507 
SpO2 § 97.37±4.94 97.87±4.56 96.47±6.08 0.656 
Hematocrit 36.50±6.97 34.87±6.06 34.87±6.06 0.616 
ICU and hospital stay, as well as IS (Inotrope score) and VIS (Vasoactive Inotropic Score) are shown for all groups. Group B had 
significantly longer hospital and ICU stay and a longer VIS score 
§ Arterial Oxygen Saturation level by Pulse Oxymeter 
 
Table 5- Vasoactive inotrope score in various groups. 
VIS Group* Group A (n=30) Group B (n=30) Group C (n=30) P value 
0 0 (0.0%) 0(0.0%) 2(6.7%) <0.001 
1 20 (66.7%) 7(23.3%) 18(60.0%) <0.001 
2 7 (23.3%) 11(36.7%) 7(23.3%) <0.001 
3 2 (6.7%) 9(30.0%) 1(3.3%) <0.001 
4 0 (0.0%) 1(3.3%) 1(3.3%) <0.001 
5 1 (3.3%) 2(6.7%) 1(3.3%) <0.001 
Death 1 (3.3%) 0(0.0%) 1(3.3%) >0.999 
* VIS: Vasoactive Inotropic Score; Breakdown of the VIS score is demonstrated for all groups. 
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procedures to improve the ventilation status of these 
patients. However, the treatment modalities mentioned 
above, aim at reducing already elevated interleukin 
levels which may have already caused damage. A 
better option would be taking measures to prevent the 
interleukins from rising in the first place thus reducing 
their deleterious effect. We hypothesize based on the 
current literature that identifying and treating patients 
with vitamin D deficiency may be effective in this 
regard. We were able to show that IL 1,6,10 and TNF-
alpha increased after placing patients on CPB in all 
groups regardless of their levels of vitamin D. There 
has been no evidence, to date, in the literature 
demonstrating the potential harms or benefits of 
treating or withholding treatment with vitamin D, in 
patients with insufficient levels just before the surgery. 
Therefore, we did not feel that withholding vitamin D 
therapy in Group A of the study (those with insufficient 
levels) was detrimental to their health in any known 
way.  
Furthermore, we did not find a meaningful 
reduction in the levels of aforementioned cytokines in 
groups of patients who were properly treated for 
vitamin D deficiency; therefore, demonstrating that 
correcting vitamin D levels just before surgery (i.e., 3 
days before operation) did not improve the surgical 
outcome, including the time spent in the hospital and 
ICU postoperatively. However, based on the results of 
our study, it remains unknown whether identifying 
patients with vitamin D deficiency and treating them 
earlier (weeks or months before surgery) would have 
had any beneficial effects.  
One of the prognostic indicators in patients 
undergoing congenital heart surgery is the use of 
postoperative inotropes including adrenaline, 
epinephrine, dopamine, and milrinone. Vitamin D may 
also play a role in reducing the use of these inotropes 
postoperatively, therefore, potentially reducing patient 
morbidity and mortality. In our study, we demonstrated 
a significant reduction in the amounts of inotropes used 
in vitamin D deficient patients who were treated with 
vitamin D before the operation; however, we did not 
see a significant improvement in the reduction of 
postoperative complications and hospitalization days, 
which may be due to our small sample size. 
 
Figure 1. Indicator for patients’ postoperative critical status level; D1: 1st postoperative day; D2: 2nd postoperative day; D3: 3rd 
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Conclusion 
No significant difference in the rates of postoperative 
parameters in patients with normal and those with 
deficient levels of vitamin D3 was observed  
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